About this trial
The aim of this clinical trial is to compare the analgesic effect of a pericapsular nerve group (PENG) block with a combined femoral, sciatic, lateral femoral cutaneous nerve block for postoperative analgesia in patients scheduled for secondary total hip arthroplasty. The primary objective of this study is to compare postoperative pain management between the PENG block and the combined block (femoral, sciatic, lateral femoral cutaneous) by measuring postoperative morphine consumption in each of the two groups.
Participants will be randomized into two groups. Patients assigned to the PENG group will receive a PENG block with ropivacaine, followed by a sham (sciatic) block, and spinal anesthesia with isobaric bupivacaine. Patients assigned to the combined block group will receive femoral, sciatic, lateral femoral cutaneous nerve blocks with ropivacaine, followed by spinal anesthesia with isobaric bupivacaine.
Eligibility criteria
Qualifiers
Male and female patients
ASA (American Society of Anaesthesiologists) I-III
18 years of age or older
Patients scheduled for elective secundary hip arthroplasty
Disqualifiers
Refusal or inability to give consent
Allergy to any of: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone
Bleeding diathesis
Neurological deficit of the operative side
Trial design
Treatments tested in this trial
- Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound
- Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine